C. Corrigan (London, United Kingdom)
Returning asthma symptoms correlate with free IgE upon omalizumab cessation
M. Humbert, P. Lowe, C. Ferioli, C. Martin, M. Blogg (Clamart, France; Basel, Switzerland; Horsham, United Kingdom)
|   |
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
K. Ohta, T. Miyamoto, M. Yamamoto, H. Fox, M. Blogg, N. Okino (Tokyo, Japan; Horsham, United Kingdom)
| |
Omalizumab and Churg-Strauss syndrome
A. M. Ruppert, D. Stanciu, G. Averous, S. Riehm, C. Debry, F. De Blay (Strasbourg, France)
| |
Clinical outcome in patients treated with omalizumab during pre-approval period in France
M. Molimard, V. Le Gros (Bordeaux, Rueil-Malmaison, France)
| |
Serum potassium level in patient of bronchial asthma on sequential nebulized salbutamol therapy
J. K. Samaria (Varanasi, India)
| |
Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients
Y. Havlucu (Hatay, Turkey)
| |
New approach to the rehabilitation of children frequently suffered from respiratory diseases
I. Borisova, S. Smirnova, V. Manchuk (Krasnoyarsk, Russian Federation)
| |
Level of sECP before and after ASIT in asthma and rhinitis patients
G. Sovljanski, M. Bogic, Z. Plavsic, D. Knezevic, I. Dedic (Belgrade, Serbia And Montenegro)
| |
Efficiency and safety of influenza vaccines in children with chronic diseases and deviations in state of health
M. Galitskaja, L. Namazova (Moscow, Russian Federation)
| |
Influence of a clinic-based group intervention on asthma perception and management in India
V. Singh, S. Singh, R. Gupta (Jaipur, Rajasthan, India)
| |
A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study
V. Wendel-Hansen, C. Lundberg, H. Lindberg, B. Sparf, S. Persson, N. Rydell, A. Perolari, M. Persson, A. Jansson, E. Landström, M. Fant, L. Larsson (Uppsala, Sweden)
| |
Study of influence of interleukin-1b on cytokines production in inflammatory sites
E. Varyushina, A. Kotov, S. Sineva, A. Demjanov, A. Simbirtsev, L. Timchuck (St. Petersburg, Russian Federation)
| |
Mimotopes for the identification of conformational epitopes of the two major mite allergens are potential candidates for epitope-specific immunotherapy
K. Szalai, M. Scheidl, J. Fuhrmanns, R. Brunner, J. Wallmann, S. Vrtala, O. Scheiner, J. M. Saint-Remy, D. Neumann, I. Schoell, E. Jensen-Jarolim (Vienna, Austria; Leuven, Belgium; Saarbrücken, Germany)
| |
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma
M. Marappan (Chennai, India)
| |
Do different vaccination regimens for BCG and hepatitis B affect the development of allergic disorders in early childhood?
D. Dilli, I. Bostanci, Y. Dallar (Ankara, Turkey)
| |
Assessment of a responder identification treatment algorithm for omalizumab in a naturalistic setting
G. Ayre, C. Anthonissen, C. Martin, F. Turk, K. Thomas (Horsham, United Kingdom; Basel, Switzerland)
| |
Refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β2 agonist inhalation: is this phenomenon airway remodeling?
H. Tanimoto, M. Taniguchi, Y. Fukutomi, C. Oshikata, E. Ono, K. Sekiya, T. Tsuburai, N. Tsurikisawa, M. Otomo, Y. Maeda, A. Mori, M. Hasegawa, K. Akiyama (Sagamihara, Japan)
| |